Blood Reviews
Volume 22, Issue 4 , Pages 221-234 , July 2008

Acute myeloid leukemia in the elderly: Conventional and novel treatment approaches

  • Chad M. Craig

      Affiliations

    • Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, CA, United States
    • Corresponding Author InformationCorresponding author.
    • ,
  • Gary J. Schiller

      Affiliations

    • Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, CA, United States

References 

  1. Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology. 2004;98–117
  2. Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. New England Journal of Medicine. 1999;341(14):1051–1062
  3. Ries LG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
  4. R. Pazdur, et al., Cancer Management: A Multidisciplinary Approach 8th edition. CMP Healthcare Media, Oncology Publishing Group: Manhasset NY, 369–385.
  5. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine. 2002;162:1597–1603
  6. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21(24):4642–4649
  7. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology. 1989;7:1268–1274
  8. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology. 1990;8:272–279
  9. Disperati P, Minden MD, Gupta V. Acute promyelocytic leukemia in patients aged 70 years and over – A single center experience of unselected patients. Leukemia & Lymphoma. 2007;48(8):1654–1658
  10. Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. British Journal of Haematology. 1994;86(1):82–91
  11. Jabbour EJ, Estey E, Kantarjian HM, et al. Adult Acute Myeloid Leukemia. Mayo Clinic Proceedings 2006;81(2): 247-260. Available at [www.mayoclinicproceedings.com].
  12. Stone RM. The Difficult Problem of Acute Myeloid Leukemia in the Older Adult. CA: A Cancer Journal for Clinicians. 2002;52:363–371
  13. Van Leeuwen FE. Risk of acute myelogenous leukemia and myelodysplasia following cancer treatment. Bailliere’s Clinical Haematology. 1996;9(1):57–85
  14. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485
  15. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New England Journal of Medicine. 1994;331(14):896–903
  16. Stone RM. Novel therapeutic agents in acute myeloid leukemia. Experimental Hematology. 2007;35:166–167
  17. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network 2003;1(4): 520–539. Updated version available at [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I%2BAgree%23site].
  18. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312–1320
  19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukemia Working Parties. Blood. 1998;92(7):2322–2333
  20. Johnson PR, Ryder WD, Yin JA. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia. British Journal of Haematology. 1995;90:954–956
  21. Johnson PR, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia. Leukemia and Lymphoma. 1994;16:51–56
  22. Kantarjian H, O’brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098
  23. Grigg AP, Reynolds J, McQuillan A, et al. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia and Lymphoma. 2005;46(3):367–375
  24. Johnson PR, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. British Journal of Haematology. 1993;85(2):300–306
  25. Zhong Z, Liu ZC, Li JW. The Clinical Observation on Arsenic Trioxide with ATRA in Treating Acute Promyelocytic Leukemia for Six Years [abstract]. Blood 2007;110(11): Abstract 2868.
  26. Fenaux P, Chevret S, de Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Practice and Research Clinical Haematology. 2003;16:495–501
  27. Sanz MA, Vellenga E, Rayon C, et al. All-transretinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104:3490–3493
  28. Latagliata R, Avvisati G, Lo Coco F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Annals of Oncology. 1997;8:1273–1275
  29. Mangelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or = 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group BIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17:1085–1090
  30. Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all transretinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19:230–233
  31. Juliusson G, Hoglund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British Journal of Haematology. 2003;123(5):810–818
  32. Ferrara F, Annunziata M, Copia C, et al. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica. 1998;83(2):126–131
  33. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology. 1998;16(3):872–881
  34. Leoni F, Ciolli S, Nozzoli C, et al. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica. 1997;82:13–18
  35. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age > or = 75 years. Cancer. 2004;101(2):231–235
  36. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479–485
  37. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdome Medical Research Council AML11trial. Blood. 2001;98:1302–1311
  38. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108(1):45–51
  39. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100:389–3876
  40. Fey MF. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients. Annals of Oncology. 2003;14:1161–1162
  41. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of Medical Research Council’s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89(7):2311–2318
  42. Bow EJ, Stuherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. Journal of Clinical Oncology. 1996;14(4):1345–1352
  43. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. British Journal of Haematology. 2006;135(4):450–474
  44. Wahlin A, Markevarn B, Golovleva I, et al. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. British Journal of Haematology. 2001;115(1):25–33
  45. Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Journal of Clinical Oncology. 2005;23(25):3404–3411
  46. Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leukemia Research. 2006;30(7):777–783
  47. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3263–3270
  48. Cheng Y, Paz K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs: The Investigational Drugs Journal. 2008;11(1):46–56
  49. Levis M, Pham R, Smith BD, et al. In vitro studies of a FLT-3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104:1145–1150
  50. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323–3329
  51. Van den Heuvel-Eibrink MM, van der Holt B, Burnett AK. CD34-related coexpression of MDR1 and BCRP indicated a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology. 2007;86(5):329–337
  52. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100(4):1224–1232
  53. Van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005;106(8):2646–2654
  54. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Journal of Clinical Oncology. 2004;22(6):1078–1086
  55. Connelly-Smith L, Pattinson J, Grundy M, et al. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Experimental Hematology. 2007;35(12):1793–1800
  56. Yang DH, Lee JJ, Mun YC, et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogenetic hematopoietic stem cell transplantation. American Journal of Hematology. 2007;82(1):1–587
  57. Wang D, Ke XY, Wang J, et al. Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia [abstract, article in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87(20): 1384-1388.
  58. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine. 1995;332:1671–1677
  59. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548–553
  60. Smith TJ, Khatcheressian J, Lyman GH, et al. Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology. 2006;24:3187–3205
  61. Burnett AK, Milligan D, Prentice , et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124
  62. Tilly H, Castaigne S, Sigaux F, et al. Treatment of acute myeloblastic leukemia in elderly patients with low-dose cytosine arabonoside [abstract, article in French]. Presse Medicale 1985;14(15): 827–831.
  63. Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leukemia & Lymphoma. 2007;48(10):1922–1930
  64. Burnett AK, Russell N, Kell JW, et al. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy [abstract]. Blood 2004;104: 248.
  65. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology. 2007;25(1):1–2
  66. Schiller GJ, DeAngelo DJ, Pigneux A, et al. Phase II Study of VNP40101M (Cloretazine) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML) [abstract]. Blood 2007;110(11): Abstract 917.
  67. Estey E. Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients. Journal of Clinical Oncology. 2007;25(14):1908–1915
  68. Bouabdallah R, Lefrere F, Rose C, et al. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia. 1999;13(10):1491–1496
  69. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology. 2007;25(25):3884–3891
  70. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006;20(2):212–217
  71. Thatikonda C, Rossetti JM, Shadduck RK, et al. Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia [abstract]. Blood 2007;110(11): Abstract 4387.
  72. Mathews V, George B, Lakshmi KM. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2527–2632
  73. Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leukemia Research. 2004;28(9):909–919
  74. Rivi R, Calleja E, Konig A, et al. Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on APL and other myeloid and lymphoid leukemia derived cell lines. Blood. 1996;88(suppl):68a
  75. Soignet SL, Tong WP, Hirschfeld S, et al. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemotherapy and Pharmacology. 1999;44(5):417–421
  76. Raza A, Jurcic JG, Roboz GJ, et al. Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33 [abstract]. Blood 2007;110(11): Abstract 159.
  77. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyl transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109(4):1387–1394
  78. Harousseau JL, Lancet JE, Reiffers J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007;109(12):5151–5156
  79. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the franesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369
  80. Raponi M, Horousseau JL, Lancet JE, et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research. 2007;13(7):2254–2260
  81. Stone RM, Mayer RJ. The approach to the elderly patient with acute myeloid leukemia. Hematology/Oncology Clinics of North America. 1993;7(1):65–79
  82. Schiffer CA, Dodge R, Larson RA. Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer. 1997;80:2210–2214
  83. Schiller G, Lee M. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia. Leukemia and Lymphoma. 1997;25:111–119
  84. Grovdal M, Khan R, Aggerholm A, et al. Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy [abstract]. Blood 2007;110(11): Abstract 818.
  85. Brune M, Sastaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88–96
  86. Saunter C, Berchtold W, Fopp M, et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984;1:379–382
  87. Champlin R, Jacobs A, Gale RP, et al. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet. 1984;1:894–896
  88. Saunter C, Alberto P, Berchtold W, et al. Long-term results of two Swiss AML studies. Haematology and Blood Transfusion. 1987;30:38–44
  89. Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high versus conventional dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high dose cytarabine. Blood. 2005;105:481–488
  90. Pautas C, Thomas X, Merabet F, et al. Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study [abstract]. Blood 2007;110(11): Abstract 162.
  91. Brune ML, Rowe JM, Szer J, et al. Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival [abstract]. Blood 2007;110(11): Abstract 1846.
  92. Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–776
  93. Alsabti EA, Taleb AM, Raji HM, et al. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia. The Japanese Journal of Experimental Medicine. 1979;49(3):157–168
  94. Berneman ZN, Driessche AV, de Velde AV, et al. Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial [abstract]. Blood 2007;110(11): Abstract 158.
  95. Li L, Giannopaulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. International Journal of Oncology. 2006;28:855–861
  96. Rezvani K,Yong SMA, Mielke S, et al. Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies [abstract]. Blood 2007;110(11): Abstract 287.
  97. Greiner J, Schmitt A, Giannopoulos, et al. Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination [abstract]. Blood 2007;110(11): Abstract 1806.
  98. Le Q, Melenhorst JJ, Hensel N, et al. Human Neutrophil Elastase Stimulating CD4+ and CD8+ Cells is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types [abstract]. Blood 2007;110(11): Abstract 1807.
  99. Ochi T, Fujiwara H, Suemori K, et al. Aurora-A Kinase: A Novel Target for the Immunotherapy Against Human Leukemias [abstract]. Blood 2007;110(11): Abstract 1796.
  100. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogenic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814
  101. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative Allogenic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20(1):128–135
  102. Bertz H, Potthoff K, Finke J. Allogenic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. Journal of Clinical Oncology. 2003;21(8):1480–1484
  103. Sayer HG, Kroger M, Beyer , et al. Reduced intensity conditioning for allogenic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31:1089–1095
  104. Blaise D, Vey N, Faucher C, et al. Current status of reduced intensity conditioning allogenic stem cell transplantation for acute myeloid leukemia. Haematologica. 2007;92(4):533–541
  105. Estey E, de Lima M, Tibes R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395–1400
  106. Schetelig J, Bornhauser M, Schmid C, et al. Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia—Results of a Retrospective Analysis in 368 Patients [abstract]. Blood 2007;110(11): Abstract 172.
  107. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85–86
  108. Herr AL, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia. 2007;21(1):129–135
  109. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–3665
  110. Ferrara F, Viola A, Copia C, et al. Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. Hematological Oncology. 2007;25:84–89
  111. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogenic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439–449
  112. Watson M, Buck G, Wheatley K, et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. European Journal of Cancer. 2004;40(7):971–978
  113. Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogenic hematopoietic cell transplantation in adults 60 years of age and older. Journal of Clinical Oncology. 2005;23(15):3439–3446
  114. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954–958
  115. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;(89):1870–1875
  116. Zhou J, Khng J, Jasinghe VJ, et al. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Research 2007; (Article in press), doi:10.1016/j.leukres.2007.11.025.
  117. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research. 2004;(11):3577–3585
  118. Douer D, Watkins K, Levine AM, et al. Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia. Leukemia & Lymphoma. 2003;44(12):2135–2136
  119. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–2386
  120. Faderl S, Gandhi V, O’Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105(3):940–947
  121. Giles F, Verstovsek S, Faderl S, et al. A phase II study of Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research. 2006;30(12):1591–1595
  122. Pagano L, Fianchi L, Caira M, et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679–3690
  123. Bross PF, Beitz J, Chen G, et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research. 2001;7:1490–1496
  124. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–77
  125. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cylcosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research. 2003;27(10):893–897
  126. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of Clinical Oncology. 2005;23:41110–41116

PII: S0268-960X(08)00022-2

doi: 10.1016/j.blre.2008.03.002

Blood Reviews
Volume 22, Issue 4 , Pages 221-234 , July 2008

Article Tools